Ria Sanghavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ria Sanghavi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Phyo Kyaw Myint
University of Aberdeen
2 shared publications - Tiberiu Alexandru Pana
Ageing Clinical and Experimental Research (ACER) Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
2 shared publications - Amer Harky
Liverpool Heart and Chest Hospital
1 shared publication - Athanasios Saratzis
NIHR Leicester Biomedical Research Centre, BHF Cardiovascular Research Facility, Leicester, UK
1 shared publication Chris Fox
Medical School
1 shared publication- Chris Fox
University of Exeter, Exeter, Devon, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 24 September 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 794-803
Is the Ankle Brachial Pressure Index an Independent Predictor for Cardiovascular Morbidity and Death in the Asymptomatic Population? A Systematic Review and Meta-analysis
- 24 September 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 794-803
Open AccessIs the Ankle Brachial Pressure Index an Independent Predictor for Cardiovascular Morbidity and Death in the Asymptomatic Population? A Systematic Review and Meta-analysis
- Open Access
- 8 September 2022
- Published by Taylor & Francis in Future Cardiology
- Vol. 18 (11) , 891-899
Outcomes in Cardiac Implantable Electronic device-related Infective Endocarditis: A Systematic Review of Current Literature
Aim: Cardiac implantable electronic device infective endocarditis is a serious infection with poor prognosis. Materials & methods: The systematic review of the literature was conducted using search...
- 8 September 2022
- Published by Taylor & Francis in Future Cardiology
- Vol. 18 (11) , 891-899
Open AccessOutcomes in Cardiac Implantable Electronic device-related Infective Endocarditis: A Systematic Review of Current Literature
Aim: Cardiac implantable electronic device infective endocarditis is a serious infection with poor prognosis. Materials & methods: The systematic review of the literature was conducted using search...
- Open Access
- 27 February 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (7) , 3297-3306
Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC‐Norfolk prospective population‐based cohort study
Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40‐79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and C‐reactive protein (CRP) were measured during 1HC and tumour necrosis factor alpha (TNF‐α) and interleukin 6 (IL‐6) during 2HC. Cross‐sectional associations between ACB and inflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, comorbidities and medications.Results: In total, 17 678 and 22 051 participants were included in cross‐sectional analyses for CRP, and fibrinogen, respectively. Furthermore, 5101 participants with data on TNF‐α and IL‐6 were included in the prospective analyses. Cross‐sectionally, compared to ACB = 0, ACB ≥ 4 was associated with higher fibrinogen, beta (95% confidence interval) = 0.134 g/L (0.070, 0.199), CRP 1.175 mg/L (0.715, 1.634), IL‐6 0.593 pg/mL (0.254, 0.932) and TNF‐α 0.137 pg/mL (0.033, 0.241). In addition, a point increase in ACB was associated with higher levels of all markers. Prospectively, compared to ACB = 0, ACB ≥ 4 was associated with higher IL‐6(pg/mL) of 0.019 (−0.323, 0.361) and TNF‐α (pg/mL) of 0.202% (0.81, 0.323). A unit increase in ACB was associated with a significantly higher TNF‐α and IL‐6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.
- 27 February 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (7) , 3297-3306
Open AccessHigher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC‐Norfolk prospective population‐based cohort study
Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40‐79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and C‐reactive protein (CRP) were measured during 1HC and tumour necrosis factor alpha (TNF‐α) and interleukin 6 (IL‐6) during 2HC. Cross‐sectional associations between ACB and inflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, comorbidities and medications.Results: In total, 17 678 and 22 051 participants were included in cross‐sectional analyses for CRP, and fibrinogen, respectively. Furthermore, 5101 participants with data on TNF‐α and IL‐6 were included in the prospective analyses. Cross‐sectionally, compared to ACB = 0, ACB ≥ 4 was associated with higher fibrinogen, beta (95% confidence interval) = 0.134 g/L (0.070, 0.199), CRP 1.175 mg/L (0.715, 1.634), IL‐6 0.593 pg/mL (0.254, 0.932) and TNF‐α 0.137 pg/mL (0.033, 0.241). In addition, a point increase in ACB was associated with higher levels of all markers. Prospectively, compared to ACB = 0, ACB ≥ 4 was associated with higher IL‐6(pg/mL) of 0.019 (−0.323, 0.361) and TNF‐α (pg/mL) of 0.202% (0.81, 0.323). A unit increase in ACB was associated with a significantly higher TNF‐α and IL‐6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.
- Open Access
- 3 June 2021
- Published by Wiley
Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study
Background: Higher anticholinergic burden from medications is associated with increased risk of cardiovascular disease and cognitive function decline. A mechanistic pathway has never been established. We aimed to determine whether chronic inflammation may mediate these associations. Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). The anticholinergic cognitive burden score (ACB) was calculated at baseline/first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Plasma fibrinogen and C-reactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNF-α) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB and inflammatory markers were examined for 1HC and 2HC, respectively. The prospective association was also examined between 1HC ACB and 2HC inflammatory markers. All models adjusted for age, sex, lifestyle factors, co-morbidities and medications. Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. A total of 5,101 participants with available data for TNF-α and IL-6 were included in the longitudinal analyses. Cross-sectionally, a point increase in the ACB was associated with a significant increase in all inflammatory markers (beta (standard error): fibrinogen – 0.035g/l (0.006), p<0.001; CRP 0.284mg/l (0.044), p<0.001; TNF-α 0.031pg/ml (0.010), p=0.002; and IL-6 0.112pg/ml (0.033), p=0.001. Longitudinally, a unit increase in the ACB was associated with a significant increase in TNF-α 0.028pg/ml (0.011), p=0.013 and IL-6 0.076 pg/ml (0.035), p=0.029. Conclusion: Higher anticholinergic burden was significantly associated with higher inflammatory markers. Inflammation may mediate the relationship between exposure to anticholinergic medications and adverse outcomes
- 3 June 2021
- Published by Wiley
Open AccessHigher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study
Background: Higher anticholinergic burden from medications is associated with increased risk of cardiovascular disease and cognitive function decline. A mechanistic pathway has never been established. We aimed to determine whether chronic inflammation may mediate these associations. Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). The anticholinergic cognitive burden score (ACB) was calculated at baseline/first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Plasma fibrinogen and C-reactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNF-α) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB and inflammatory markers were examined for 1HC and 2HC, respectively. The prospective association was also examined between 1HC ACB and 2HC inflammatory markers. All models adjusted for age, sex, lifestyle factors, co-morbidities and medications. Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. A total of 5,101 participants with available data for TNF-α and IL-6 were included in the longitudinal analyses. Cross-sectionally, a point increase in the ACB was associated with a significant increase in all inflammatory markers (beta (standard error): fibrinogen – 0.035g/l (0.006), p<0.001; CRP 0.284mg/l (0.044), p<0.001; TNF-α 0.031pg/ml (0.010), p=0.002; and IL-6 0.112pg/ml (0.033), p=0.001. Longitudinally, a unit increase in the ACB was associated with a significant increase in TNF-α 0.028pg/ml (0.011), p=0.013 and IL-6 0.076 pg/ml (0.035), p=0.029. Conclusion: Higher anticholinergic burden was significantly associated with higher inflammatory markers. Inflammation may mediate the relationship between exposure to anticholinergic medications and adverse outcomes